Overview

  • Product nameAnti-CHST3 antibody
    See all CHST3 primary antibodies
  • Description
    Rabbit polyclonal to CHST3
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide conjugated to KLH, corresponding to a region within N terminal amino acids 32-62 of Human CHST3 (NP_004264.2)

  • Positive control
    • Mouse spleen tissue lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab107093 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 55 kDa.

Target

  • FunctionCatalyzes the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices. Can also sulfate Gal residues of keratan sulfate, another glycosaminoglycan, and the Gal residues in sialyl N-acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a role in the maintenance of naive T-lymphocytes in the spleen.
  • Tissue specificityWidely expressed in adult tissues. Expressed in heart, placenta, skeletal muscle and pancreas. Also expressed in various immune tissues such as spleen, lymph node, thymus and appendix.
  • Involvement in diseaseDefects in CHST3 are a cause of spondyloepiphyseal dysplasia with congenital joint dislocations (SEDC-JD) [MIM:143095]. A bone dysplasia clinically characterized by dislocation of the knees and/or hips at birth, clubfoot, elbow joint dysplasia with subluxation and limited extension, short stature, and progressive kyphosis developing in late childhood. The disorder is usually evident at birth, with short stature and multiple joint dislocations or subluxations that dominate the neonatal clinical and radiographic picture. During childhood, the dislocations improve, both spontaneously and with surgical treatment, and features of spondyloepiphyseal dysplasia become apparent, leading to arthritis of the hips and spine with intervertebral disk degeneration, rigid kyphoscoliosis, and trunk shortening by late childhood.
  • Sequence similaritiesBelongs to the sulfotransferase 1 family. Gal/GlcNAc/GalNAc subfamily.
  • Cellular localizationGolgi apparatus membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • C6ST 1 antibody
    • C6ST antibody
    • C6ST-1 antibody
    • C6ST1 antibody
    • Carbohydrate (chondroitin 6) sulfotransferase 3 antibody
    • Carbohydrate sulfotransferase 3 antibody
    • Chondroitin 6 O sulfotransferase 1 antibody
    • Chondroitin 6 sulfotransferase antibody
    • Chondroitin 6-O-sulfotransferase 1 antibody
    • Chondroitin 6-sulfotransferase antibody
    • CHST 3 antibody
    • Chst3 antibody
    • CHST3_HUMAN antibody
    • Galactose/N acetylglucosamine/N acetylglucosamine 6 O sulfotransferase 0 antibody
    • Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0 antibody
    • GST 0 antibody
    • GST-0 antibody
    • GST0 antibody
    see all

Anti-CHST3 antibody images

  • Anti-CHST3 antibody (ab107093) at 1/100 dilution + Mouse spleen tissue lysate at 35 µg

    Predicted band size : 55 kDa

References for Anti-CHST3 antibody (ab107093)

ab107093 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab107093.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"